Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
Description: Regimen related ≥ grade 3 toxicity within 48 hours of first infusion (DLT)
Measure: Regimen related ≥ grade 3 toxicity within 48 hours of first infusion Time: 48 hoursDescription: Alive and not intubated 28 days after the date of first infusion
Measure: 28-day treatment success, defined as S28 Time: 28 daysDescription: Time to extubation
Measure: Time to extubation Time: 28 daysDescription: Oxygenation requirement (PaO2/FiO2) change between day 0 and day +11
Measure: Oxygenation improvement Time: 11 daysDescription: Ventilator free days measured at day 28
Measure: Ventilator free days Time: 28 daysDescription: Organ failure free days measured at day 28
Measure: Organ failure free days Time: 28 daysDescription: ICU free days measured at day 28
Measure: ICU free days Time: 28 daysDescription: All-cause mortality at day 28
Measure: All-cause mortality Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports